Loading
A phase 2 trial of Ilixadencel run by Mendus, completed.
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) is a phase 2 interventional study registered as NCT02432846 by Mendus, with 88 participants enrolled, started 2015-04. Conditions recorded: Renal Cell Carcinoma, Metastatic. Interventions recorded: Intuvax (INN: ilixadencel) and Sunitinib.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/